Imagine facing a life-threatening illness, knowing a drug exists that could significantly extend your life, but being denied access simply because of where you live. This was the harsh reality for many men in England battling prostate cancer, until now. Thankfully, after tireless campaigning, the life-extending drug abiraterone is finally set to be offered to thousands of men in England, bringing hope and potentially saving hundreds of lives.
For years, abiraterone has been available on the National Health Service (NHS) in Scotland and Wales, offering a vital lifeline to men with prostate cancer. But here's where it gets controversial... In England and Northern Ireland, its availability was restricted to only the most severe, advanced cases where the cancer had already spread (metastasized). This created a postcode lottery, where access to potentially life-saving treatment depended on geographical location. The drug is already prescribed for patients in the UK with very advanced prostate cancer that has spread. Now, this is changing, and thousands more men will benefit.
Now, NHS England has announced that abiraterone will be made available to high-risk patients whose cancer hasn't yet spread. This decision is a major victory for patients, charities, and advocates who have fought tirelessly for wider access to this crucial medication. Amy Rylance, assistant director of health improvement at Prostate Cancer UK, described the decision as a "momentous, life-saving victory," acknowledging the profound impact it will have on countless lives. She also praised the BBC for their consistent coverage of the issue, which helped maintain public awareness and pressure on decision-makers.
Prostate Cancer UK estimates that around 7,000 men each year will now be able to begin abiraterone treatment. And this is the part most people miss... The charity believes this wider access will prevent approximately 1,470 men from experiencing the devastating news that their cancer has worsened, and could potentially save around 560 lives. NHS England anticipates that the drug will be available within weeks, with approximately 2,000 men recently diagnosed with prostate cancer potentially benefiting from the treatment if deemed clinically appropriate.
So, how does abiraterone work? In simple terms, it stops cancer from spreading by cutting off its hormone supply. Prostate cancer cells rely on hormones to grow and multiply. Abiraterone interferes with the body's ability to produce these hormones, effectively starving the cancer and slowing its progression.
The story of Giles Turner from Brighton exemplifies the frustration and injustice many men faced. Diagnosed with aggressive prostate cancer in March 2023, Giles discovered that abiraterone was readily available on the NHS in Scotland and Wales, but not in England. "I was shocked and angered that my postcode meant I was denied free access to a treatment that could halve my risk of dying and give me the best chance of a cure," he said. Forced to pay £250 a month for private treatment, Giles became a vocal advocate for change, highlighting the unfairness of the situation for those who couldn't afford it. He began his campaign for a change of policy.
While NHS England initially reviewed the drug's use, officials later informed Prostate Cancer UK that funding was unavailable, a sentiment echoed by ministers in early 2025. "Today's wonderful news is the culmination of all our determined and dogged efforts," said Mr. Turner, expressing his relief and happiness that men like him will now have fair access to effective treatment. But he added that he was frustrated that nearly three years had passed since he raised the issue.
The evidence supporting abiraterone's effectiveness comes from a significant trial called STAMPEDE, published in 2022. This trial demonstrated improved survival rates among men who received abiraterone alongside standard care. The Institute of Cancer Research highlighted that two years of abiraterone treatment halved the risk of prostate cancer recurrence and reduced the risk of death by 40%. Researchers had expressed their frustration that NICE (National Institute for Health and Care Excellence) had not approved the drug for newly diagnosed patients.
But for NICE and the medical regulator the MHRA to consider extending a drug's usage they need detailed and time-consuming applications. And here's a critical point: in October 2022, abiraterone's patent expired. This meant that other companies could manufacture and sell the drug, reducing the financial incentive for the original manufacturer to pursue wider approval. This situation begs the question: should there be different approval pathways for off-patent drugs with proven benefits, ensuring that patients aren't denied access due to bureaucratic hurdles and lack of commercial incentive?
While Scotland and Wales found ways to provide the drug within existing protocols, England lagged behind. NHS England has now stated that savings on other medications have made it possible to fund the expanded availability of abiraterone. Prof Peter Johnson, national clinical director for cancer at NHS England, emphasized that this life-extending treatment will offer thousands of men a better chance of living longer and healthier lives. Health and social care Secretary Wes Streeting echoed this sentiment, highlighting the importance of every day spent with loved ones when living with prostate cancer.
Prof Gert Attard, co-lead of the STAMPEDE trial, hailed the decision as a "hugely welcome moment for patients," emphasizing that the research clearly demonstrated the drug's ability to save lives when administered earlier. Prostate Cancer UK is now focusing its efforts on Northern Ireland, urging decision-makers to follow suit and ensure equitable access to abiraterone for all men affected by prostate cancer. Stormont has yet to comment on any plans to change how abiraterone is prescribed.
This victory in England raises important questions about healthcare access and the role of advocacy in driving change. Did the system fail men in England for too long, and what can be done to prevent similar situations in the future? How much weight should be given to cost-effectiveness when determining access to potentially life-saving treatments? And finally, do you think that postcode lotteries in healthcare are ever acceptable, or should access to essential medication be uniform across the country? Share your thoughts and experiences in the comments below.
